Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is awarding Syntiron US$1.7 million to develop a maternal vaccine that targets Escherichia coli and Klebsiella pneumoniae, two bacterial species that cause a large portion of neonatal sepsis infections.
Synendos Therapeutics AG has received approval from the European Medicines Agency (EMA) to initiate a first-in-human trial of its lead asset, SYT-510, a first-in-class inhibitor that modulates a newly identified drug target in the endocannabinoid system (ECS) to restore healthy brain physiology.
Researchers from Springworks Therapeutics Inc. and affiliated organizations presented the discovery and preclinical characterization of a novel covalent and irreversible YAP/TAZ-TEAD inhibitor, SWTX-143, being developed for the treatment of mesothelioma.
Ratio Therapeutics Inc. has closed a $50 million series B financing to expand application of its proprietary technology platforms, Trillium and Macropa, to develop novel best-in-class radiopharmaceuticals.
Cantharidin, a natural product coming from blister beetles, has anti-proliferative activity in several cancer cell lines such as leukemia, myeloma or colon cancer cells.
There is increasing interest in studying exosome molecules, and particularly long non-coding RNAs (lncRNAs), in the diagnosis of gastric cancer. Microarray analysis was performed from samples obtained from patients with gastric cancer who underwent endoscopic resection.
Researchers at ETH Zurich have identified a proteomic signature that could recognize long COVID six months after acute infection. Biologically, the signature indicated that the complement system remained active in patients with long COVID six months after infection. Translationally, it could lead to a diagnostic test for long COVID, and suggests that targeting the complement system could be a therapeutic approach to prevent or treat the disorder.
RSS
